Withdrawing Guilty Pleas on “Rushed Signing” and Medication Grounds Requires Objective Proof of Impairment—Demeanor and Rule 11 Admissions Control Even Absent an Express Medication Question

1. Introduction

In United States v. Donald Stenson, the Seventh Circuit affirmed the denial of a defendant’s post-plea motion to withdraw guilty pleas to two counts of sex trafficking of a minor under 18 U.S.C. §§ 1591(a)(1), (b)(2), (c), and 1596(a)(1). The prosecution alleged that Stenson, over multiple trips to the Philippines, solicited minors (ages 11–17) for sex acts in exchange for money, gifts, and food. He initially faced broader charges, including violations of 18 U.S.C. § 2423(c) and (e) and additional sex-trafficking counts.

After a Rule 11 change-of-plea hearing, Stenson sought to withdraw his pleas. His central theory on appeal was that the plea was not knowing and voluntary because (i) he felt rushed into signing the plea agreement the morning of the hearing, and (ii) an anti-anxiety medication (Clonazepam) materially affected his cognition and made him “compliant.” The district court held an evidentiary hearing and denied relief; the Seventh Circuit affirmed.

The key legal issue is the threshold a defendant must meet to show a “fair and just reason” to withdraw a plea—particularly when the defendant’s later claims conflict with his contemporaneous Rule 11 statements and the written plea agreement, and when the alleged impairment is supported only by a defendant’s affidavit and general medication side-effect information.

2. Summary of the Opinion

The Seventh Circuit held that the district court did not abuse its discretion in denying Stenson’s motion to withdraw his guilty plea. It also held the district court’s factual finding—that the plea was knowing and voluntary—was not clearly erroneous.

• “Rushed” plea-agreement review: The court relied on the plea colloquy and the written plea agreement, both of which reflected that Stenson reviewed and understood the agreement, was satisfied with counsel, and pleaded voluntarily.
• Medication impairment: The district judge observed no signs of confusion, distress, or rote “yes” answers; Stenson asked clarifying questions when needed and gave specific, appropriate responses. His signed agreement also disclaimed impairment from drugs or medication. General side-effect material from Drugs.com was insufficient; under Seventh Circuit precedent, a defendant typically needs an affidavit from a qualified psychiatrist to substantiate medication-related cognitive impairment where the plea proceeding revealed no impairment.
• Colloquy completeness: Although the district court did not expressly ask whether Stenson had taken impairing medication, the overall colloquy, combined with the judge’s first-hand observations and the plea agreement’s terms, supported voluntariness.

3. Analysis

3.1 Precedents Cited (and Their Role)

• United States v. Barr, 960 F.3d 906 (7th Cir. 2020): Set the appellate standard of review—denial of a plea-withdrawal motion is reviewed for abuse of discretion. The Stenson panel anchored its posture in deference to the district court’s management of plea withdrawal.
• United States v. Kamkarian, 79 F.4th 889 (7th Cir. 2023): Supplied both (i) the clear error standard for factual findings on voluntariness/knowledge and (ii) the “three broad reasons” framework for “fair and just reason” (innocence, ineffective assistance, or an unknowing/involuntary plea). Stenson proceeded solely on the third ground.
• United States v. Akinsola, 105 F.3d 331 (7th Cir. 1997): Two key contributions: (i) an appellate court reviews the written plea agreement alongside the Rule 11 colloquy when a defendant is represented by counsel and the agreement is elaborate; (ii) a broader policy observation that guilty pleas are central to the criminal system—supporting the judiciary’s insistence on finality once a plea is accepted.
• United States v. Mitchell, 58 F.3d 1221 (7th Cir. 1995): Reinforced the “entire record” approach; Stenson could not isolate a single snippet of transcript to overcome the full record of admissions and assurances.
• United States v. Milquette, 214 F.3d 859 (7th Cir. 2000): Emphasized that there is no “unlimited right” to withdraw a plea after acceptance; the burden remains on the defendant under Rule 11.
• Fed. R. Crim. P. 11(d)(2)(B): The governing rule: after acceptance (but before sentencing), a defendant must show a “fair and just reason” to withdraw. The opinion applies this standard stringently, particularly where the defendant contradicts sworn Rule 11 admissions.
• United States v. Collins, 796 F.3d 829 (7th Cir. 2015): Provided the “heavy burden of persuasion” language and a critical institutional point: courts should credit the judge’s impressions at the plea hearing over later “bare protestations,” otherwise pleas become an “empty ceremony.” This case underwrote deference to the district judge’s assessment of Stenson’s demeanor.
• United States v. Messino, 55 F.3d 1241 (7th Cir. 1995): Supplied the “uphill battle” principle—when a defendant later contradicts his Rule 11 statements that the plea was knowing and voluntary, withdrawal becomes difficult to justify.
• United States v. Groll, 992 F.2d 755 (7th Cir. 1993): Stated that district courts are generally justified in discrediting proffered withdrawal reasons and holding defendants to their Rule 11 admissions—directly supporting the district court’s rejection of Stenson’s post hoc narrative.
• United States v. Merrill, 23 F.4th 766 (7th Cir. 2022) & Strickland v. Washington, 466 U.S. 668 (1984): Although Stenson did not pursue ineffective assistance on appeal, the opinion (via a footnote) recited the Strickland framework as the standard when ineffective assistance is alleged to have caused an unknowing/involuntary plea—clarifying the doctrinal map of withdrawal grounds.
• United States v. Fountain, 777 F.2d 351 (7th Cir. 1985): Recognized that a dialogue is the best method for ensuring voluntariness and factual basis, but also that Rule 11 dialogue “will vary from case to case.” The panel used Fountain to address the missing explicit “medication” question: while encouraged, it is not invariably required if the totality of the colloquy and observations support comprehension.
• United States v. Hardimon, 700 F.3d 940 (7th Cir. 2012): The controlling medication-impairment precedent. Hardimon rejected the assumption that taking common psychotropic medication itself proves impaired decisionmaking and held that, when plea inquiries were adequate and revealed no impairment, a defendant needs an affidavit from a qualified psychiatrist to describe adverse impacts and indications of impairment. Stenson’s reliance on general side-effect listings mirrored (and fell short of) Hardimon’s evidentiary requirement.
• United States v. Peterson, 414 F.3d 825 (7th Cir. 2005): Supported the proposition that judges need not allow litigants to contradict themselves readily—bolstering the skepticism toward Stenson’s after-the-fact claims.

3.2 Legal Reasoning

(a) Total-record review of voluntariness. The panel treated voluntariness as a total-record question, explicitly considering the written plea agreement and the live colloquy together (per United States v. Akinsola and United States v. Mitchell). This methodological move is decisive: Stenson’s arguments targeted perceived gaps or ambiguities in discrete moments, but the broader record was uniform—he confirmed he reviewed the agreement with counsel, understood it, was satisfied with counsel, and was pleading voluntarily.

(b) “Rushed” signing claim undermined by admissions and opportunity to object. The opinion highlights an exchange where the court asked whether Stenson had gone over the plea agreement with his lawyer, reached an understanding, and signed it—he answered “Yes.” The district court reasoned (and the Seventh Circuit agreed) that if Stenson truly lacked time, that moment was his opportunity to say so. The written plea agreement further confirmed review and understanding. The appellate court found no clear error in treating these as reliable indicators of a knowing and voluntary plea.

(c) Medication impairment requires more than generalized side-effect evidence. The panel accepted the district court’s credibility assessment: the judge observed Stenson and saw no signs of confusion or distress; Stenson asked for clarification when he did not understand a question; and he gave more-than-monosyllabic answers (e.g., “Very satisfied, Your Honor.”). This directly countered the narrative of being cognitively impaired or merely compliant.

The court then addressed the documentary contradiction: Stenson signed a plea agreement affirming he was not under the influence of any drug or medication impairing his understanding. Stenson attempted to exploit a perceived timing issue about when he signed, but his own affidavit and “rushed” argument corroborated the district court’s finding that he signed the amended agreement that morning—making the impairment-disclaimer especially probative.

(d) Missing explicit “medication” question did not invalidate the plea colloquy. The panel acknowledged that the district court did not expressly ask whether Stenson had taken medication that might impair understanding, and it “encourage[d]” courts to cover the topic. But invoking United States v. Fountain (case-by-case variation) and United States v. Collins (credit the judge’s impressions), the court held the overall colloquy was not inadequate because the judge’s observations and the rest of the record revealed no impairment.

(e) Evidentiary insufficiency under Hardimon. Stenson’s proof consisted of (i) his own affidavit/testimony and (ii) an online list of possible side effects from Drugs.com. Applying United States v. Hardimon, the panel held this was not enough to overcome an otherwise adequate plea colloquy showing no apparent impairment; the required showing typically includes an affidavit from a qualified psychiatrist linking the medication to actual impairment and identifying indicia of impairment. Stenson offered no such expert evidence.

3.3 Impact

• Strengthened “totality-of-the-record” discipline in plea-withdrawal litigation: The opinion signals that defendants cannot cherry-pick minor colloquy omissions (like a missing medication question) to negate extensive sworn admissions in the transcript and plea paperwork.
• Medication-based withdrawal claims face an evidentiary gatekeeping rule: Consistent with United States v. Hardimon, generalized side-effect lists and self-reporting are unlikely to suffice where the plea hearing record shows comprehension; objective, expert evidence is essential.
• Practical guidance for district courts: While not making a new constitutional requirement, the panel “encourage[d]” judges to ask explicitly about impairing substances. This is best read as risk management: asking the question can help foreclose later claims, even though omission will not necessarily be reversible error.
• Predictability and finality in pleas: By emphasizing deference to the plea judge’s observations and to Rule 11 admissions (United States v. Collins, United States v. Groll, United States v. Messino), the decision reinforces plea finality—especially salient in high-stakes prosecutions where post-plea regret is foreseeable.

4. Complex Concepts Simplified

• Rule 11 colloquy: The judge’s in-court Q&A with the defendant before accepting a guilty plea. Its purpose is to ensure the defendant understands the charge, the rights being waived, and the consequences, and that the plea is voluntary.
• “Knowing and voluntary” plea: “Knowing” means the defendant understood what he was doing and the consequences; “voluntary” means the plea was not the product of coercion or incapacity.
• Motion to withdraw a guilty plea (pre-sentencing): After the court accepts a plea but before sentencing, the defendant may withdraw only by showing a “fair and just reason” (Fed. R. Crim. P. 11(d)(2)(B)).
• Standards of review:
  • Abuse of discretion: appellate court gives substantial leeway to the trial judge’s decision.
  • Clear error: appellate court defers to factual findings unless strongly convinced a mistake was made.
• Demeanor evidence: The trial judge’s real-time observations (confusion, hesitation, coherence) that can be highly persuasive because the appellate court reads only the paper record.
• Why expert evidence matters for medication claims: Many medications list possible cognitive side effects; courts generally require an expert to connect the medication to impairment in the particular defendant at the particular time, rather than relying on generic possibilities.

5. Conclusion

United States v. Donald Stenson reaffirms a stringent, record-centered approach to plea withdrawal. A defendant who confirmed—both orally during the Rule 11 colloquy and in the written plea agreement—that he understood the deal and entered it voluntarily bears a “heavy” burden to undo that plea. Claims of being “rushed” or cognitively impaired by medication will generally fail without objective, case-specific evidence—particularly expert support when the plea hearing itself showed no signs of impairment. The opinion thus preserves the finality of accepted guilty pleas while offering practical guidance: district courts should ask about impairing medications when feasible, but the constitutionality and adequacy of a colloquy will still be judged by the totality of the record.